Findings

What do systematic reviews say?

90 questions · 97 findings · 9 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 25 · 25.8%GRADE not reported 4 · 4.1%Very low 15 · 15.5%Low 34 · 35.1%Moderate 18 · 18.6%High 1 · 1%

Potent/very potent topical corticosteroids vs no topical corticosteroids

Low birthweight · pregnant women

Potent/very potent topical corticosteroids may leads to higher low birth weight compared with no topical corticosteroids (low certainty).

1 finding from 1 review

Safety of topical corticosteroids in pregnancy 2015 · Cochrane Headline outcomes only
RR 1.58
47651 participants
Low

Potent/very potent topical corticosteroids vs no topical corticosteroids

Preterm birth · pregnant women

Potent/very potent topical corticosteroids may leads to higher preterm delivery compared with no topical corticosteroids (low certainty).

1 finding from 1 review

Safety of topical corticosteroids in pregnancy 2015 · Cochrane Headline outcomes only
RR 1.05
47651 participants
Low

Potent/very potent topical corticosteroids vs no topical corticosteroids

Foetal death · pregnant women

Potent/very potent topical corticosteroids may leads to higher foetal death compared with no topical corticosteroids (low certainty).

1 finding from 1 review

Safety of topical corticosteroids in pregnancy 2015 · Cochrane Headline outcomes only
RR 1.14
37086 participants
Low

Potent/very potent topical corticosteroids vs no topical corticosteroids

Low Apgar score · pregnant women

Potent/very potent topical corticosteroids may leads to higher low Apgar score compared with no topical corticosteroids (low certainty).

1 finding from 1 review

Safety of topical corticosteroids in pregnancy 2015 · Cochrane Headline outcomes only
RR 1.03
7514 participants
Low

Topical steroid vs comparator

Change in severity · infantile seborrhoeic dermatitis (including cradle cap)

1 finding from 1 review

Interventions for infantile seborrhoeic dermatitis (including cradle cap) 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 105 participants
Very low

Topical steroid vs comparator

Adverse events · infantile seborrhoeic dermatitis (including cradle cap)

1 finding from 1 review

Interventions for infantile seborrhoeic dermatitis (including cradle cap) 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 105 participants
Very low

Topical steroid vs comparator

Quality of life · infantile seborrhoeic dermatitis (including cradle cap)

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for infantile seborrhoeic dermatitis (including cradle cap) 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tacrolimus 0.03% vs corticosteroids

Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis

Tacrolimus 0.03% probably leads to higher physician's assessment of global response of improvement, clear or… compared with corticosteroids (moderate certainty).

4 findings from 1 review

Topical tacrolimus for atopic dermatitis 2015 · Cochrane Headline outcomes only
RR 2.05 [1.36, 3.08]
1 study · 411 participants
Moderate
Topical tacrolimus for atopic dermatitis 2015 · Cochrane Headline outcomes only
RR 2.58 [1.96, 3.38]
2 studies · 790 participants
Moderate
Topical tacrolimus for atopic dermatitis 2015 · Cochrane Headline outcomes only
RR 0.45 [0.13, 1.57]
2 studies · 409 participants
Very low

Show 1 more finding

Topical tacrolimus for atopic dermatitis 2015 · Cochrane Headline outcomes only
RR 1 [0.85, 1.19]
1 study · 265 participants
Low

Tacrolimus 0.03% vs corticosteroids

Adverse effects ‐ burning · people with atopic dermatitis

1 finding from 1 review

Topical tacrolimus for atopic dermatitis 2015 · Cochrane Headline outcomes only
2.48 [1.96, 3.14]
5 studies · 1883 participants
High

Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention

Eating a normally varied diet · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
No studies reported this outcome.
0 studies
No studies found

Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention

Restoration of sexual activity · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
None of the included studies assessed the effectiveness of treatments of genital ELP; thus, this outcome was not reported.
0 studies
No studies found

Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention

Reduction in number of flares · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
No studies reported this outcome.
0 studies
No studies found

Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention

Reduction in severity of flares · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
No studies reported this outcome.
0 studies
No studies found

Oat‐containing moisturisers vs vehicle or no moisturiser

Total amount of topical corticosteroids used · people with eczema

1 finding from 1 review

Emollients and moisturisers for eczema 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 222 participants
Low

Moisturisers vs vehicle, placebo or no moisturiser

Total amount of topical corticosteroids used · people with eczema

1 finding from 1 review

Emollients and moisturisers for eczema 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 222 participants
Low

Moisturisers vs no treatment (no moisturiser)

Amount of corticosteroids used · people with eczema

1 finding from 1 review

Emollients and moisturisers for eczema 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 222 participants
Low

IVIg vs corticosteroids

Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs corticosteroids

Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs corticosteroids

Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs corticosteroids

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found